Prolgolimab plus chemotherapy improves long term survival in advanced nonsquamous NSCLC

Extended interval tarlatamab dosing shows consistent clinical activity in previously treated SCLC

Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC

JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses

2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact, adherence challenges, and nursing management

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care

ASCO 2026: Lung cancer roundup

ASCO 2026: Highlights and analysis

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC